RxDoctor Payments DataLook up a doctor →

Jason Foerst, MD

Interventional Cardiology · Roanoke, VANPI 1255435293

Payments from drug & device makers

$955,573in general payments, 2019–2025

Across 845 payments — averaging $1130.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$460K
  • Boston Scientific$212K
  • Medtronic$203K
  • Abbott$70K
  • Ancora Heart, Inc.$8K
  • Abiomed$860
  • plus $1K from 12 others
$12,603in research payments, 2019–2025

Across 32 payments — averaging $393.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$13K

What the payments were for

  • Consulting fees$31,58218%
  • Speaking & faculty fees$81,82747%
  • Travel & lodging$36,88721%
  • Food & beverage$24,70014%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$955,573 in reported general payments places this provider in the 95th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$356,666
Medicare patients
722
Services billed
1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$164,349
EntrestoSacubitril/Valsartan98$94,275
JardianceEmpagliflozin59$84,675
OzempicSemaglutide18$17,684
Repatha SureclickEvolocumab12$13,065
Metoprolol Succinate158$1,956
Amiodarone Hcl47$1,318
Furosemide237$1,207
Carvedilol127$1,035
Atorvastatin Calcium109$1,008
Potassium Chloride47$899
ClopidogrelClopidogrel Bisulfate85$789
Bumetanide28$787
SotalolSotalol Hcl54$781
Isosorbide Mononitrate ErIsosorbide Mononitrate88$727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$164,349144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →